Monte Rosa Therapeutics Inc. (GLUE)
GLUE trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/0001193125-26-109360-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GLUE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001826457 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $123.7M |
| Net income | -$38.6M |
| Operating income | -$54.2M |
| Net margin | -31.2% |
| Operating margin | -43.8% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $129.9M |
| Total assets | $448.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-11 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-01 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 399 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.9% |
| 1 month | -24.0% |
| 3 months | -57.4% |
| Year to date | -37.1% |
| 1 year | -5.1% |
| From 52-week high | -61.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SLBT | SL Science Holding Limited | $1.53 | +1.32% | $858.0M |
| ODTX | Odyssey Therapeutics Inc. | $17.24 | -5.59% | $828.5M |
| CGEM | Cullinan Therapeutics Inc. | $14.10 | -5.69% | $907.4M |
| DNA | Ginkgo Bioworks Holdings Inc. | $11.76 | -0.25% | $756.6M |
| MGTX | MeiraGTx Holdings plc | $9.94 | -4.24% | $954.7M |
| SANA | Sana Biotechnology Inc. | $2.41 | -8.02% | $721.5M |
| CADL | Candel Therapeutics Inc. | $9.27 | -5.21% | $709.3M |
| IMTX | Immatics N.V. | $6.83 | -5.27% | $1.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier